COMPANY

Intralytix Inc.

HQ: Columbia, MD source · intralytix.com ↗ · Mid-Atlantic

Location: Columbia, MD · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Vancomycin-Resistant Enterococcal Colonization Shigellosis Crohn Disease VRELysin™ bacteriophage Bacteriophage preparation

3Trials (company is sponsor)9NIH grants

Timeline

Oct 25, 2023 Trial start Phase 1/Phase 2: Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects source ↗
Feb 23, 2023 Trial start Phase 1/Phase 2: Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis source ↗
May 1, 2019 Trial start Phase 1/Phase 2: Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT05715619	Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects	Phase 1/Phase 2	Suspended	Oct 25, 2023	Oct 31, 2026 (estimated)
NCT05182749	Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis	Phase 1/Phase 2	Active, not recruiting	Feb 23, 2023	Dec 9, 2024 (actual)
NCT03808103	Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease	Phase 1/Phase 2	Active, not recruiting	May 1, 2019	Jun 1, 2026 (estimated)

NIH awards 9

Annual award amounts. Total $9.1M.

Apr 11, 2024 NIH award 5U01AI148054-05 FY2024: $1,162,758 awarded for that fiscal year; activity U01 (OTHER_NIH); PI SULAKVELIDZE, ALEXANDER; recipient as written: INTRALYTIX, INC., Columbia, MD. Bacteriophage-based approach for source ↗
Apr 19, 2023 NIH award 5U01AI148054-04 FY2023: $1,172,622 awarded for that fiscal year; activity U01 (OTHER_NIH); PI SULAKVELIDZE, ALEXANDER; recipient as written: INTRALYTIX, INC., Columbia, MD. Bacteriophage-based approach for source ↗
May 18, 2022 NIH award 5U01AI148054-03 FY2022: $1,171,611 awarded for that fiscal year; activity U01 (OTHER_NIH); PI SULAKVELIDZE, ALEXANDER; recipient as written: INTRALYTIX, INC., Columbia, MD. Bacteriophage-based approach for source ↗
2022 NIH contract (government contract; not a grant and not an investment round) 75N93021C00034-P00005-9999-1 FY2022: $1,498,045 awarded for that fiscal year; activity N44 (OTHER_NIH); PI RUZICKA, MEL; recipient as written: INTRALYTIX, INC., Columbia, MD. A univers source ↗
Apr 26, 2021 NIH award 5U01AI148054-02 FY2021: $1,439,728 awarded for that fiscal year; activity U01 (OTHER_NIH); PI SULAKVELIDZE, ALEXANDER; recipient as written: INTRALYTIX, INC., Columbia, MD. Bacteriophage-based approach for source ↗
2021 NIH contract (government contract; not a grant and not an investment round) 75N93021C00034-0-9999-1 FY2021: $299,672 awarded for that fiscal year; activity N43 (OTHER_NIH); PI RUZICKA, MEL; recipient as written: INTRALYTIX, INC., Columbia, MD. A universal, sca source ↗
May 4, 2020 NIH award 1U01AI148054-01 FY2020: $1,952,644 awarded for that fiscal year; activity U01 (OTHER_NIH); PI SULAKVELIDZE, ALEXANDER; recipient as written: INTRALYTIX, INC., Columbia, MD. Bacteriophage-based approach for source ↗
Sep 21, 2007 NIH award 1R43AT003236-01A1 FY2007: $269,232 awarded for that fiscal year; activity R43 (SBIR); PI SULAKVELIDZE, ALEXANDER; recipient as written: INTRALYTIX, INC., BALTIMORE, MD. Bacteriophage-based probiotic prepara source ↗
Jun 29, 2000 NIH award 1R41AI045185-01A1 FY2000: $99,929 awarded for that fiscal year; activity R41 (STTR); PI MORRIS, JOHN GLENN; recipient as written: INTRALYTIX, INC., BALTIMORE, MD. LIMITATION OF SALMONELLA COLONIZATION WITH source ↗